News
08-06-2015, 06:21 AM
Celsion Corporation, an oncology drug development company, today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC).
More... (http://www.news-medical.net/news/20150806/Celsion-reports-updated-results-from-HEAT-Study-of-ThermoDox-in-patients-with-primary-liver-cancer.aspx)
More... (http://www.news-medical.net/news/20150806/Celsion-reports-updated-results-from-HEAT-Study-of-ThermoDox-in-patients-with-primary-liver-cancer.aspx)